AMD Clinical Trial
Official title:
Post-approval Study of VisionCare's Implantable Miniature Telescope (by Dr. Isaac Lipshitz) in Patients With Bilateral Severe to Profound Central Vision Impairment Assoc. With End-stage Age-related Macular Degeneration
The objective of the PAS-01 study is to assess the safety of the intraocular as measured by
the cumulative incidence of patients who within 5 years after implantation experience
persistent vision-impairing corneal edema (corneal edema leading to persistent loss of best
corrected distance visual acuity >2 lines from pre-surgery baseline level).
The study will test the null hypothesis that the percentage of patients who experience
persistent vision-impairing corneal edema is >17% against the alternative that the percentage
is <17%. The null hypothesis will be rejected if the upper bound of the two-sided 95%
confidence integral for the observed percentage is <17%.
ECD sub-study. At investigative sites participating in the ECD Sub-Group study, corneal endothelial cell density will be measured by non-contact specular microscopy in a subgroup of 150 patients enrolled in the IMT-PAS-01 in the eye schedule for and implanted with the intraocular telescope at study entry, 3 months, 12, months, 24 months, 36 months, 48 months and 60 months. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Recruiting |
NCT03893474 -
Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners
|
N/A | |
Completed |
NCT00971464 -
Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation
|
Phase 2 | |
Terminated |
NCT00332657 -
Anecortave Acetate Risk Reduction Trial (AART)
|
Phase 3 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT01766596 -
Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort)
|
N/A | |
Completed |
NCT03322930 -
Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
|
||
Completed |
NCT01778491 -
AMD Phenotype and Genotype Study
|
||
Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
Active, not recruiting |
NCT03845582 -
Phase 3 Study of ALK-001 in Geographic Atrophy
|
Phase 3 | |
Completed |
NCT03372746 -
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
|
||
Completed |
NCT03367767 -
Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
|
||
Terminated |
NCT00333216 -
Anecortave Acetate Risk-Reduction Trial (AART)
|
Phase 3 | |
Completed |
NCT01570790 -
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00346866 -
Anecortave Acetate Versus Placebo in AMD Patients Following PDT
|
Phase 2 | |
Withdrawn |
NCT00726466 -
Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
|
Phase 1 | |
Completed |
NCT00306488 -
OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
|
Phase 2 | |
Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT01632527 -
Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01339949 -
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
|
N/A |